Evidence map›Paper›PMID 39425218›Full record

ArticleActa neuropathologica communications2024

Acquisition of neurodegenerative features in isogenic OPTN(E50K) human stem cell-derived retinal ganglion cells associated with autophagy disruption and mTORC1 signaling reduction.

Kang-Chieh Huang, Cátia Gomes, Yukihiro Shiga, Nicolas Belforte, Kirstin B VanderWall, Sailee S Lavekar, Clarisse M Fligor, Jade Harkin, Shelby M Hetzer, Shruti V Patil and 2 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Neuroinflammation in glaucoma: a myriad of cellular pathways and players.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Generation of xenobiotic free retinofugal assembloids.Frontiers in cell and developmental biology · 2025
    Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Kang-Chieh HuangDepartment of Biology, Indiana University Purdue University Indianapolis, Indianapolis, IN, USA.
Cátia GomesStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Yukihiro ShigaDepartment of Neuroscience, University of Montreal, Montreal, QC, Canada.
Nicolas BelforteDepartment of Neuroscience, University of Montreal, Montreal, QC, Canada.
Kirstin B VanderWallDepartment of Biology, Indiana University Purdue University Indianapolis, Indianapolis, IN, USA.
Sailee S LavekarDepartment of Biology, Indiana University Purdue University Indianapolis, Indianapolis, IN, USA.
Clarisse M FligorDepartment of Biology, Indiana University Purdue University Indianapolis, Indianapolis, IN, USA.
Jade HarkinStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Shelby M HetzerStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Shruti V PatilStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Adriana Di PoloDepartment of Neuroscience, University of Montreal, Montreal, QC, Canada.
Jason S MeyerStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA. meyerjas@iu.edu.ORCID 0000-0001-9037-6033

Funding

Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucomaU24EY033269 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI FORTUNE, BRAD, MEYER, JASON STEPHEN · 2021 to 2025
$7.0M
Retinal Ganglion Cell Dendrite and Synapse Regeneration in Glaucoma: the Role of Insulin Signaling.R01EY030838 · NEI · CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (UNIVERSITY OF MONTREAL HOSPITAL) · PI DI POLO, ADRIANA, FORTUNE, BRAD · 2020 to 2024
$2.9M
Establishing a human cellular model of retinal ganglion cell compartmentalization in neurodegeneration and neuroinflammationR01EY033022 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI Jason Stephen Meyer · 2021 to 2026
$2.7M
BrightFocus Foundation G2020369BrightFocus Foundation G2022003FCIHR 458569Fonds de Recherche du Québec - Santé 276181Gilbert Family Foundation 923016Indiana State Department of Health 26343NCATS NIH HHS UL1 TR002529NEI NIH HHS R01 EY030838NEI NIH HHS R01EY030838NEI NIH HHS R01 EY033022NEI NIH HHS R01EY033022NEI NIH HHS U24 EY033269NEI NIH HHS U24EY033269
6 · The paper itself

Abstract

The ability to derive retinal ganglion cells (RGCs) from human pluripotent stem cells (hPSCs) has led to numerous advances in the field of retinal research, with great potential for the use of hPSC-derived RGCs for studies of human retinal development, in vitro disease modeling, drug discovery, as well as their potential use for cell replacement therapeutics. Of all these possibilities, the use of hPSC-derived RGCs as a human-relevant platform for in vitro disease modeling has received the greatest attention, due to the translational relevance as well as the immediacy with which results may be obtained compared to more complex applications like cell replacement. While several studies to date have focused upon the use of hPSC-derived RGCs with genetic variants associated with glaucoma or other optic neuropathies, many of these have largely described cellular phenotypes with only limited advancement into exploring dysfunctional cellular pathways as a consequence of the disease-associated gene variants. Thus, to further advance this field of research, in the current study we leveraged an isogenic hPSC model with a glaucoma-associated mutation in the Optineurin (OPTN) protein, which plays a prominent role in autophagy. We identified an impairment of autophagic-lysosomal degradation and decreased mTORC1 signaling via activation of the stress sensor AMPK, along with subsequent neurodegeneration in OPTN(E50K) RGCs differentiated from hPSCs, and have further validated some of these findings in a mouse model of ocular hypertension. Pharmacological inhibition of mTORC1 in hPSC-derived RGCs recapitulated disease-related neurodegenerative phenotypes in otherwise healthy RGCs, while the mTOR-independent induction of autophagy reduced protein accumulation and restored neurite outgrowth in diseased OPTN(E50K) RGCs. Taken together, these results highlighted that autophagy disruption resulted in increased autophagic demand which was associated with downregulated signaling through mTORC1, contributing to the degeneration of RGCs.

Indexed as

AutophagyCell Cycle ProteinsMechanistic Target of Rapamycin Complex 1Retinal Ganglion CellsSignal TransductionAnimalsHumansMembrane Transport ProteinsMicePluripotent Stem CellsCell Cycle ProteinsMechanistic Target of Rapamycin Complex 1Membrane Transport ProteinsOPTN protein, human

Identifiers

PMID39425218
PMCPMC11487784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.